※이 정보는 고수의 추천주식에서 생산한 것이 아닌 외부에서 얻은 정보를 공유하는 것입니다
※제공하는 정보는 투자판단의 참고자료이며, 투자판단의 최종책임은 본 정보를 열람하시는 이용자에게 있습니다
빌게이츠 재단 지원 CEPI, 이노비오에 $5,600만 달러 지원결정 **진원생명과학 ( 011000) Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS https://globenewswire.com/news-release/2018/04/11/1468470/0/en/Inovio-Awarded-up-to-56-Million-from-CEPI-to-Advance-DNA-Vaccines-Against-Lassa-Fever-and-MERS.html CEPI will fund up to $56,000,000 to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use. To date, CEPI has received multi-year funding from Norway, Germany, Japan, the Bill & Melinda Gates Foundation and Wellcome.
0
0
0
